Complete guides, comparisons and scientific analyses on peptides in skincare, health and biohacking.
A neutral look at a practice that spread through social media and some clinics faster than any study could follow it.
Approved prescription medicines, vials labeled 'for research use only', cosmetics and food supplements do not share the same legal status. Here is what the official texts say, as of September 30, 2026.
A reference guide to the preserved diluent found in multi-dose vials: composition, labeled indications, shelf life after first entry, and the documented neonatal contraindication.
Retatrutide is an investigational triple GIP, GLP-1 and glucagon receptor agonist. This review covers only the adverse effects reported in peer-reviewed trials and registrational readouts, always alongside the placebo comparison.
Klow Blend targets tissue repair, skin and inflammation. MOTS-c is a mitochondrial-encoded peptide studied for metabolism and exercise capacity. Here is how they actually compare, and what the literature does and does not say about combining them.
What animal studies report, what the single human trial of a MOTS-c analog found, and why the honest answer to "is it safe?" is still "nobody knows."
A source-by-source look at every documented MOTS-c dose, why no validated human protocol exists, and how to read a vial label without guessing.
A rigorous look at alanyl-histidyl-lysine copper, the lesser known cousin of GHK-Cu: its chemistry, the mechanisms studied in cell culture, and where the evidence genuinely stops.
A reference table, not a protocol. One rule (1 unit = 0.01 mL) converts any vial size and any volume of bacteriostatic water into micrograms per syringe unit.
A week-by-week look at tirzepatide outcomes in the SURMOUNT trials, and the things a before-and-after photo can never tell you.
What peer-reviewed research describes about pigmentation timelines, plausible tanning phases, documented adverse effects, and the unresolved safety and regulatory questions surrounding this alpha-MSH analog.
A neutral, data-driven look at how fast weight loss appears with the triple GIP/GLP-1/glucagon agonist, dose by dose and month by month.